Glioblastoma Multiforme Market: Rapid Growth & Investment Outlook to 2034 - DelveInsight

DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioblastoma Multiforme Market Forecast
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Glioblastoma Multiforme Market Report:
• The Glioblastoma Multiforme market size was valued approximately USD 835 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In October 2025, The U.S. Food and Drug Administration has awarded orphan drug designation to an exosome-based therapy being developed by Exousia Pro as a potential treatment for patients with glioblastoma multiforme.
• In August 2025, A new clinical study targeting patients with recurrent glioblastoma multiforme, an aggressive and hard-to-treat brain tumor, received clearance from the U.S. Food and Drug Administration. Starlight Therapeutics announced that its investigational new drug (IND) application has been approved for a Phase Ib/2a trial evaluating the combination of its novel candidate STAR-001 (LP-184) with the FDA-approved drug spironolactone. The trial will specifically enroll adult patients whose GBM has progressed following initial treatment.
• In June 2025, Diakonos Oncology, a U.S.-based biotechnology firm, secured $20 million through a private placement of Simple Agreements for Future Equity (SAFE) to accelerate its Phase II glioblastoma trial of dubodencel. The investment will also support the expansion of its clinical portfolio into additional indications, including refractory melanoma. The funding round included participation from new backers such as Baylor College of Medicine and the Brain Tumor Investment Fund, alongside existing investors, including the company's CEO, Mike Wicks.
• In May 2025, According to a press release from Roswell Park Comprehensive Cancer Center, the Phase 2b SURVIVE study (NCT05163080) evaluating SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will proceed based on interim trial data analysis.
• In November 2024, Kazia Therapeutics revealed that the FDA has scheduled a Type C meeting for December 2024 to explore possible registration pathways for paxalisib, the company's blood-brain barrier-penetrant PI3K/mTOR inhibitor, aimed at treating newly diagnosed Glioblastoma Multiforme.
• In November 2024, Novocure announced that the US FDA has approved its new HFE transducer arrays for use with OPTUNE GIO in the treatment of adult patients with Glioblastoma Multiforme
• Among the 7MM, the United States held the highest market share for Glioblastoma Multiforme treatment, amounting to approximately USD 70 million in 2023.
• In 2023, the distribution of incident cases of Glioblastoma Multiforme across the 7MM showed that the US contributed around 41%, while EU4 and the UK collectively accounted for 51%, and Japan represented 8% of the total cases.
• In 2023, within the EU4 and the UK, glioblastoma had the highest number of incident cases based on histological classification, totaling around 17,550 cases. In contrast, giant cell glioblastoma had the fewest cases, approximately 150, with numbers projected to rise by 2034.
• In Japan, during 2023, the largest share of cases in the targeted therapy pool was attributed to first-line treatments, totaling 2,690 cases, followed by second-line and subsequent treatments, which accounted for 1,365 cases.
• Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix,Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology,Inovio Pharmaceuticals, Northwest Biotherapeutics and others
• Key Glioblastoma Multiforme Therapies: Durvalumab, DNX-2401, ONC201, DCVax-L, Regorafenib, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
• The Glioblastoma Multiforme epidemiology based on gender analyzed that Glioblastoma Multiforme is more prevalent among males than females
• The Glioblastoma Multiforme market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics.

Glioblastoma Multiforme Overview
Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant brain tumor, classified as a grade IV astrocytoma. It originates from the supportive tissue of the brain called glial cells, specifically astrocytes. GBM is highly invasive, infiltrating nearby brain tissue, and rapidly growing, often leading to significant neurological symptoms and poor prognosis.

Get a Free sample for the Glioblastoma Multiforme Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glioblastoma Multiforme Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glioblastoma Multiforme Epidemiology Segmentation:
The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Glioblastoma Multiforme
• Prevalent Cases of Glioblastoma Multiforme by severity
• Gender-specific Prevalence of Glioblastoma Multiforme
• Diagnosed Cases of Episodic and Chronic Glioblastoma Multiforme

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiology Forecast
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glioblastoma Multiforme Therapies and Key Companies
• Durvalumab: AstraZeneca
• DNX-2401: DNAtrix
• ONC201: Chimerix
• DCVax-L: Northwest Therapeutics
• Regorafenib: Bayer
• Paxalisib(GDC-0084): Kazia Therapeutics
• AV-GBM-1: Aivita Biomedical
• MDNA55: Medicenna Therapeutics
• VAL-083: Kintara Therapeutics

Discover more about therapies set to grab major Glioblastoma Multiforme market share @ Glioblastoma Multiforme Treatment Landscape
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glioblastoma Multiforme Market Strengths
• Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for GBM
• Owing to the launch of bevacizumab biosimilars, a reduction in cost burden can be witnessed

Glioblastoma Multiforme Market Opportunities
• Numerous failed clinical trials suggest combination therapies willikely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties
• Better prognostic markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly preventing disease progression

Scope of the Glioblastoma Multiforme Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix,Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology,Inovio Pharmaceuticals, Northwest Biotherapeutics, and others
• Key Glioblastoma Multiforme Therapies: Durvalumab, DNX-2401, ONC201, DCVax-L, Regorafenib, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
• Glioblastoma Multiforme Therapeutic Assessment: Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies
• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme market drivers and Glioblastoma Multiforme market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Glioblastoma Multiforme Unmet Needs, KOL's views, Analyst's views, Glioblastoma Multiforme Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.